Press Releases MannKind Corporation

Equities

MNKD

US56400P7069

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
4.23 ^USD	+1.20%		+1.20%	+16.21%

Mar. 26	MannKind CFO Binder to Retire in April, Names New CFO	MT
Mar. 26	MannKind Corporation Announces Chief Financial Officer Changes, Effective April 22, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MannKind Repays Certain Debt Obligations	Apr. 03	AQ
MannKind Announces CFO Transition	Mar. 26	AQ
INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps	Mar. 11	AQ
MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8	Mar. 05	AQ
MannKind Corporation Announces Participation at Upcoming Conferences	Mar. 04	AQ
MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development Update	Feb. 27	AQ
MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024	Feb. 20	AQ
MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®	Feb. 15	AQ
MannKind Announces Up To $200 Million Royalty Purchase Agreement With Sagard Healthcare	Jan. 09	AQ
MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 Million	Jan. 02	AQ
MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference	Dec. 28	AQ
MannKind : HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT MANNKIND CORPORATION TREATS AS PRIVATE OR CONFIDENTIAL. AGREEMENT - Form 8-K	Dec. 27	PU
MannKind: Q3 Earnings Snapshot	Nov. 07	AQ
MannKind Corporation Reports 2023 Third Quarter Financial Results	Nov. 07	AQ
MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 Diabetes	Nov. 06	AQ
MannKind Corporation to Hold 2023 Third Quarter Financial Results Conference Call on November 7, 2023	23-10-31	AQ
MannKind Expands Patent Portfolio With New Clofazimine Formulation Patent	23-10-30	AQ
MannKind Corporation Announces Participation at Upcoming Conferences	23-09-05	AQ
MannKind : Second Quarter 2023 Earnings Call Presentation	23-08-07	PU
MannKind: Q2 Earnings Snapshot	23-08-07	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MannKind Corporation

Equities

MNKD

US56400P7069

Press Releases

Filters